FR3038517B1 - USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY - Google Patents

USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY Download PDF

Info

Publication number
FR3038517B1
FR3038517B1 FR1556399A FR1556399A FR3038517B1 FR 3038517 B1 FR3038517 B1 FR 3038517B1 FR 1556399 A FR1556399 A FR 1556399A FR 1556399 A FR1556399 A FR 1556399A FR 3038517 B1 FR3038517 B1 FR 3038517B1
Authority
FR
France
Prior art keywords
fragments
modified
immunotherapy
affinity
fcrn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1556399A
Other languages
French (fr)
Other versions
FR3038517A1 (en
Inventor
Philippe Mondon
Celine Monnet Mars
Alexandre Fontayne
Christophe de Romeuf
Abdessatar Chtourou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1556399A priority Critical patent/FR3038517B1/en
Application filed by LFB SA filed Critical LFB SA
Priority to AU2016290761A priority patent/AU2016290761B2/en
Priority to CA2990354A priority patent/CA2990354A1/en
Priority to PCT/FR2016/051708 priority patent/WO2017006052A2/en
Priority to JP2018500412A priority patent/JP2018524355A/en
Priority to US15/742,268 priority patent/US20180355034A1/en
Priority to CN202111105793.XA priority patent/CN113817049A/en
Priority to EP16747826.2A priority patent/EP3319989A2/en
Priority to CN201680051282.5A priority patent/CN108026163B/en
Publication of FR3038517A1 publication Critical patent/FR3038517A1/en
Application granted granted Critical
Publication of FR3038517B1 publication Critical patent/FR3038517B1/en
Priority to JP2020212333A priority patent/JP7102496B2/en
Priority to AU2022204834A priority patent/AU2022204834A1/en
Priority to JP2022109002A priority patent/JP2022137152A/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La présente invention a trait à l'utilisation de fragments Fc d'anticorps dans le traitement de maladies auto-immunes et/ou inflammatoires, lesdits fragments Fc étant des fragments Fc recombinants isolés, ayant une affinité modifiée pour au moins un des récepteurs Fc (FcR), en particulier une affinité accrue au FcRn.The present invention relates to the use of Fc fragments of antibodies in the treatment of autoimmune and / or inflammatory diseases, said Fc fragments being isolated recombinant Fc fragments, having a modified affinity for at least one of the Fc receptors ( FcR), in particular an increased affinity to FcRn.

FR1556399A 2015-07-06 2015-07-06 USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY Active FR3038517B1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR1556399A FR3038517B1 (en) 2015-07-06 2015-07-06 USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY
CN201680051282.5A CN108026163B (en) 2015-07-06 2016-07-06 Use of modified Fc fragments in immunotherapy
PCT/FR2016/051708 WO2017006052A2 (en) 2015-07-06 2016-07-06 Use of modified fc fragments in immunotherapy
JP2018500412A JP2018524355A (en) 2015-07-06 2016-07-06 Use of modified Fc fragments in immunotherapy
US15/742,268 US20180355034A1 (en) 2015-07-06 2016-07-06 Use of modified fc fragments in immunotherapy
CN202111105793.XA CN113817049A (en) 2015-07-06 2016-07-06 Use of modified Fc fragments in immunotherapy
AU2016290761A AU2016290761B2 (en) 2015-07-06 2016-07-06 Use of modified FC fragments in immunotherapy
CA2990354A CA2990354A1 (en) 2015-07-06 2016-07-06 Use of modified fc fragments in immunotherapy
EP16747826.2A EP3319989A2 (en) 2015-07-06 2016-07-06 Use of modified fc fragments in immunotherapy
JP2020212333A JP7102496B2 (en) 2015-07-06 2020-12-22 Use of modified Fc fragments in immunotherapy
AU2022204834A AU2022204834A1 (en) 2015-07-06 2022-07-06 Use of modified Fc fragments in immunotherapy
JP2022109002A JP2022137152A (en) 2015-07-06 2022-07-06 Use of modified Fc fragments in immunotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1556399 2015-07-06
FR1556399A FR3038517B1 (en) 2015-07-06 2015-07-06 USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY

Publications (2)

Publication Number Publication Date
FR3038517A1 FR3038517A1 (en) 2017-01-13
FR3038517B1 true FR3038517B1 (en) 2020-02-28

Family

ID=54937180

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1556399A Active FR3038517B1 (en) 2015-07-06 2015-07-06 USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY

Country Status (8)

Country Link
US (1) US20180355034A1 (en)
EP (1) EP3319989A2 (en)
JP (3) JP2018524355A (en)
CN (2) CN108026163B (en)
AU (2) AU2016290761B2 (en)
CA (1) CA2990354A1 (en)
FR (1) FR3038517B1 (en)
WO (1) WO2017006052A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3834851A1 (en) 2010-12-30 2021-06-16 Laboratoire Français du Fractionnement et des Biotechnologies Glycols as pathogen inactive agents
TW201509432A (en) 2013-07-05 2015-03-16 Lab Francais Du Fractionnement Matrix of affinity chromatography
FR3038517B1 (en) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY
WO2018146317A1 (en) * 2017-02-10 2018-08-16 Genmab B.V. Polypeptide variants and uses thereof
FR3064007A1 (en) * 2017-03-20 2018-09-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies ANTIBODIES FOR THE TREATMENT OF CANCERS
FR3075200B1 (en) * 2017-12-15 2022-12-23 Lab Francais Du Fractionnement VARIANTS WITH FC FRAGMENT HAVING INCREASED AFFINITY FOR FCRN AND INCREASED AFFINITY FOR AT LEAST ONE FC FRAGMENT RECEIVER
WO2020045545A1 (en) * 2018-08-29 2020-03-05 中外製薬株式会社 Antibody half-molecule, and method for inhibiting homodimer formation of antibody half-molecule
CN111825770B (en) * 2019-04-16 2023-06-09 成都医学院 Long-acting interleukin 21-Fc fusion protein and application thereof
CN114829407A (en) * 2019-09-23 2022-07-29 南开大学 Screening for Fc γ R specific binding Fc Using mammalian display
WO2023104128A1 (en) * 2021-12-09 2023-06-15 上海宝济药业有限公司 Fc polypeptide having altered glycosylation modification

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8421551D0 (en) 1984-08-24 1984-09-26 Ici Plc Water-soluble dye
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (en) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement MONOCLONAL ANTIBODIES ANTI-D
KR100787073B1 (en) 2000-06-28 2007-12-21 글리코파이, 인크. Methods for producing modified glycoproteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
FR2816319B1 (en) 2000-11-08 2004-09-03 Millegen USE OF DNA MUTAGEN POLYMERASE FOR THE CREATION OF RANDOM MUTATIONS
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
ATE503829T1 (en) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP-FUCOSE TRANSPORT
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
US6994292B2 (en) 2002-10-18 2006-02-07 The Procter & Gamble Company Dispensing apparatus for web material
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20050160485A1 (en) 2003-03-18 2005-07-21 Kyowa Hakko Kogyo Co., Ltd. Mouse in which genome is modified
US20040219143A1 (en) 2003-04-30 2004-11-04 Bluth Martin Heath Methods for recombinant immunoglobulin treatment
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
US20060223147A1 (en) 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006133148A2 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
KR20080068089A (en) 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use
PL1945665T3 (en) 2005-10-21 2012-02-29 Genzyme Corp Antibody-based therapeutics with enhanced adcc activity
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2007099988A1 (en) 2006-02-28 2007-09-07 Kyowa Hakko Kogyo Co., Ltd. α-1,6-FUCOSYLTRANSFERASE MUTANT AND USE THEREOF
CN107011445B (en) * 2007-06-01 2021-06-29 马里兰大学巴尔的摩分校 Immunoglobulin constant region Fc receptor binding agents
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
EP2537864B1 (en) * 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
TW201817745A (en) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
AU2012355710B2 (en) * 2011-12-19 2017-11-02 The Rockefeller University Non-sialylated anti-inflammatory polypeptides
KR102104686B1 (en) * 2012-01-10 2020-04-24 바이오젠 엠에이 인코포레이티드 Enhancement of transport of therapeutic molecules across the blood brain barrier
BR112014026740B1 (en) * 2012-04-27 2022-10-04 Bioatla, Llc ANTIBODY, COMPOSITION, METHOD FOR DELIVERING AN ADCC-ENHANCED ANTIBODY, AND, USE OF AN ANTIBODY
EP3424952A1 (en) * 2013-03-15 2019-01-09 Amgen, Inc Heterodimeric bispecific antibodies
CN106103476B (en) * 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn antagonists and methods of use
FR3035879A1 (en) * 2015-05-07 2016-11-11 Lab Francais Du Fractionnement MUTANTS FC WITH MODIFIED FUNCTIONAL ACTIVITY
FR3038517B1 (en) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY

Also Published As

Publication number Publication date
JP7102496B2 (en) 2022-07-19
CN108026163A (en) 2018-05-11
WO2017006052A3 (en) 2017-04-20
AU2022204834A1 (en) 2022-07-28
AU2016290761B2 (en) 2022-04-07
CN108026163B (en) 2021-10-08
JP2021050235A (en) 2021-04-01
FR3038517A1 (en) 2017-01-13
CN113817049A (en) 2021-12-21
JP2022137152A (en) 2022-09-21
JP2018524355A (en) 2018-08-30
CA2990354A1 (en) 2017-01-12
WO2017006052A2 (en) 2017-01-12
US20180355034A1 (en) 2018-12-13
EP3319989A2 (en) 2018-05-16

Similar Documents

Publication Publication Date Title
FR3038517B1 (en) USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MY197854A (en) Antibodies against signal-regulatory protein alpha and methods of use
SG10201908259WA (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
MA38498A1 (en) Anti-lag-3 binding proteins
EA201792184A1 (en) ANTIBODIES DIRECTED AGAINST T-CELL IMMUNOGLOBULIN AND MUTIN PROTEIN 3 (TIM-3)
EA201792583A1 (en) METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS
EA202092825A1 (en) ANTI-SIRPA ANTIBODIES AND METHODS OF THEIR APPLICATION
MA40801A1 (en) Anti-cd3 antibody, anti-cd123 antibody and bispecific antibodies binding specifically to cd3 and / or cd123
NZ722055A (en) Fcrn antagonists and methods of use
EA201692192A1 (en) Fcrn Anti-Body Binding for the Treatment of Autoimmune Diseases
PH12015501656A1 (en) Anti-il-33 antibodies and use thereof
MX2020007527A (en) Treatment of ophthalmologic diseases.
PE20170768A1 (en) IMPROVED AB PROTOFIBRILL BINDING ANTIBODIES
MA51907A (en) DOSAGE FOR TREATMENT WITH IL-22 FC FUSION PROTEIN
MX2022008337A (en) Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding.
CR20170539A (en) RGma UNION PROTEIN AND ITS USE
MX2021007093A (en) Anti-btla antibodies.
EA201690469A1 (en) Fusion protein
EA201991464A1 (en) ANTIBODY TO α-SINUCLEIN AND ITS APPLICATION
PH12020551805A1 (en) Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
MX2019000887A (en) Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding.
MX2021001915A (en) Method and chromatography system for determining amount and purity of a multimeric protein.
CR20210332A (en) Antibody that binds to vegf and il-1beta and methods of use
MX2022000847A (en) Dosing for prevention or treatment of graft versus host disease (gvhd) with il-22 fc fusion proteins.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20170113

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

CA Change of address

Effective date: 20221108

PLFP Fee payment

Year of fee payment: 9